{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:19:28Z","timestamp":1790140768564,"version":"4.0.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20210324113802006 JCYJ2022053015180024 JCYJ20210324113613035"],"award-info":[{"award-number":["JCYJ20210324113802006 JCYJ2022053015180024 JCYJ20210324113613035"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The biologics for moderate to severe ulcerative colitis (UC) have expanded with an increasing array. We performed an updated network meta-analysis to evaluate and compare the relative efficacy and safety profiles of biologics in moderate to severe UC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>We searched literature to 18 May 2024, to identify eligible studies. The clinical remission, clinical response, or endoscopic improvement, stratified by previous exposure or naive to biologics, and safety were assessed. A network meta-analysis was performed through the bayesian model, obtaining pairwise relative ratios (RR) and 95% confidence intervals (CI). The surface under the cumulative ranking probabilities (SUCRA) was used to rank the included agents for each outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 23 trials (10,839 patients) were included. In induction therapy, based on achieving clinical remission and endoscopic improvement, infliximab 5\u00a0mg\/kg ranked first. For clinical response, ustekinumab 6\u00a0mg\/kg superior to other drugs. Infliximab 5\u00a0mg\/kg demonstrated superior efficacy in biologic-naive patients, whereas ustekinumab 6\u00a0mg\/kg was the most effective in biologic-exposed patients. No significant differences between active interventions were observed when assessing safety outcomes, except for visilizumab. In maintenance therapy, for clinical remission and endoscopic improvement, vedolizumab 108\u00a0mg every other week and vedolizumab 300\u00a0mg every 4\u00a0weeks ranked first respectively, with infliximab 5\u00a0mg\/kg performed best in achieving clinical response. Regarding safety ranking, golimumab 100\u00a0mg was the lowest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this network meta-analysis, infliximab and vedolizumab emerged as the most effective biologics for inducing and maintaining efficacy outcomes for patients with UC. Most drugs were found to be safe and well-tolerated, with ustekinumab and mirikizumab exhibiting particularly favorable safety profiles.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1602024","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:10:36Z","timestamp":1752221436000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["What is the optimal biological therapy for moderate to severe ulcerative colitis: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Longbin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoru","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/ecco-jcc\/jjab010","article-title":"Efficacy of oral, topical, or combined oral and topical 5-Aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis","volume":"15","author":"Barberio","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J. Comput. Graph. Statistics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2021","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12876-023-02938-6","article-title":"Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis","volume":"23","author":"Chu","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","article-title":"Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/nejmoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ajg.2011.410","article-title":"Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis","volume":"107","author":"Ford","year":"","journal-title":"Am. J. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cgh.2011.10.043","article-title":"Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis","volume":"10","author":"Ford","year":"","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00535-017-1326-1","article-title":"Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)","volume":"52","author":"Hibi","year":"2017","journal-title":"J. Gastroenterol."},{"key":"B15","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2024","journal-title":"Cochrane"},{"key":"B16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2036.2006.02974.x","article-title":"The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort","volume":"24","author":"Ho","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/MCG.0000000000000319","article-title":"Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis","volume":"49","author":"Jiang","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0212989","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00535-025-02216-0","article-title":"First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study","volume":"60","author":"Naganuma","year":"2025","journal-title":"J. Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e115065","DOI":"10.1371\/journal.pone.0115065","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Neupane","year":"2014","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using bayesian network meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1053\/j.gastro.2022.02.033","article-title":"Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results","volume":"162","author":"Pan\u00e9s","year":"2022","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis [published correction appears in N engl J med. 2006 may 18;354(20):2200]","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb \u03b27) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"B39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B45","article-title":"Comparative efficacy of biologics and small molecule therapies in improving patient-reported outcomes in ulcerative colitis: systematic review and network meta-analysis","volume":"13","author":"Shehab","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol. Health"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J. Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1458998","DOI":"10.3389\/fmed.2024.1458998","article-title":"Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis - a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial","volume":"11","author":"Talar-Wojnarowska","year":"2024","journal-title":"Front. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2468-1253(21)00295-8","article-title":"Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1602024\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:10:37Z","timestamp":1752221437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1602024\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1602024"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1602024","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"article-number":"1602024"}}